Soligenix, Inc. (LON:0A6I)
1.370
+0.020 (1.48%)
At close: Nov 5, 2025
Soligenix Employees
As of December 31, 2024, Soligenix had 16 total employees, including 14 full-time and 2 part-time employees. The number of employees increased by 1 or 6.67% compared to the previous year.
Employees
16
Change (1Y)
1
Growth (1Y)
6.67%
Revenue / Employee
n/a
Profits / Employee
-504.12K GBP
Market Cap
8.84M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 16 | 1 | 6.67% |
| Dec 31, 2023 | 15 | 0 | - |
| Dec 31, 2022 | 15 | 0 | - |
| Dec 31, 2021 | 15 | -3 | -16.67% |
| Dec 31, 2020 | 18 | 2 | 12.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| HSBC Holdings | 211,304 |
| Unilever | 115,964 |
| BP p.l.c. | 100,500 |
| Shell | 96,000 |
| AstraZeneca | 94,300 |
| GSK plc | 68,629 |
| Rio Tinto Group | 60,000 |
| British American Tobacco p.l.c. | 48,989 |
Soligenix News
- 22 days ago - Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma - PRNewsWire
- 4 weeks ago - Soligenix (SNGX) Advances Phase 3 CTCL Study with Positive Safety Review - GuruFocus
- 4 weeks ago - Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma - PRNewsWire
- 4 weeks ago - Insider Buying: Christopher Schaber Acquires Shares of Soligenix Inc (SNGX) - GuruFocus
- 5 weeks ago - Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma - PRNewsWire
- 5 weeks ago - Soligenix Announces Closing of $7.5 Million Public Offering - PRNewsWire
- 5 weeks ago - Soligenix (SNGX) Launches Public Offering to Raise $7.5 Million - GuruFocus
- 5 weeks ago - Soligenix Prices 7.5 Mln Public Offering At $1.35/shr; Stock Up In Pre-market - Nasdaq